Advertisement
Screener

Lineage Cell Therapeutics, Inc. (LCTX) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Lineage Cell Therapeutics, Inc. Operating Cash Flow

Lineage Cell Therapeutics, Inc. (LCTX) reported Operating Cash Flow of -$15.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06

  • Lineage Cell Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$7.24M.
  • Lineage Cell Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$8.08M.
  • Lineage Cell Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$4.88M.
  • Lineage Cell Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.62M.
  • Lineage Cell Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$18.92M.
  • Lineage Cell Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$23.09M.
  • Lineage Cell Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$28.57M, a 2797.45% decline from fiscal 2022.
  • Lineage Cell Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was $1.06M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-30-$7.24M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$15.32M
10-Q · filed 2026-08-06
-$20.20M
derived: sum of 3 quarters · filed 2026-08-06
-$23.82M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$8.08M
10-Q · filed 2026-05-12
-$12.96M
derived: sum of 2 quarters · filed 2026-05-12
-$16.57M
derived: sum of 3 quarters · filed 2026-05-12
-$22.11M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$4.88M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
-$8.49M
derived: sum of 2 quarters · filed 2026-03-05
-$14.03M
derived: sum of 3 quarters · filed 2026-08-06
-$18.92M
10-K · filed 2026-03-05
2025-09-30-$3.62M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$9.15M
derived: sum of 2 quarters · filed 2026-08-06
-$14.04M
10-Q · filed 2025-11-06
-$20.39M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$5.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$10.43M
10-Q · filed 2026-08-06
-$16.77M
derived: sum of 3 quarters · filed 2026-08-06
-$22.56M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$4.89M
10-Q · filed 2026-05-12
-$11.23M
derived: sum of 2 quarters · filed 2026-05-12
-$17.02M
derived: sum of 3 quarters · filed 2026-05-12
-$22.20M
derived: sum of 4 quarters · filed 2026-05-12
2024-12-31-$6.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
-$12.13M
derived: sum of 2 quarters · filed 2026-03-05
-$17.31M
derived: sum of 3 quarters · filed 2026-03-05
-$23.09M
10-K · filed 2026-03-05
2024-09-30-$5.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$10.96M
derived: sum of 2 quarters · filed 2025-11-06
-$16.75M
10-Q · filed 2025-11-06
-$22.77M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30-$5.18M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
-$10.96M
10-Q · filed 2025-08-12
-$16.98M
derived: sum of 3 quarters · filed 2025-08-12
-$22.02M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31-$5.78M
10-Q · filed 2025-05-13
-$11.80M
derived: sum of 2 quarters · filed 2025-05-13
-$16.84M
derived: sum of 3 quarters · filed 2025-05-13
-$23.11M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$6.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10
-$11.06M
derived: sum of 2 quarters · filed 2025-03-10
-$17.32M
derived: sum of 3 quarters · filed 2025-03-10
-$28.57M
10-K · filed 2025-03-10
2023-09-30-$5.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
-$11.30M
derived: sum of 2 quarters · filed 2024-11-14
-$22.55M
10-Q · filed 2024-11-14
-$30.85M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30-$6.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$17.51M
10-Q · filed 2024-08-08
-$25.81M
derived: sum of 3 quarters · filed 2024-08-08
-$31.29M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$11.24M
10-Q · filed 2024-05-09
-$19.55M
derived: sum of 2 quarters · filed 2024-05-09
-$25.02M
derived: sum of 3 quarters · filed 2024-05-09
-$32.09M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$8.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07
-$13.78M
derived: sum of 2 quarters · filed 2024-03-07
-$20.84M
derived: sum of 3 quarters · filed 2024-03-07
$1.06M
10-K · filed 2024-03-07
2022-09-30-$5.48M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$12.54M
derived: sum of 2 quarters · filed 2023-11-09
$9.36M
10-Q · filed 2023-11-09
$3.49M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30-$7.06M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$14.84M
10-Q · filed 2023-08-10
$8.97M
derived: sum of 3 quarters · filed 2023-08-10
$4.12M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$21.90M
10-Q · filed 2023-05-11
$16.03M
derived: sum of 2 quarters · filed 2023-05-11
$11.18M
derived: sum of 3 quarters · filed 2023-05-11
$5.77M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31-$5.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09
-$10.72M
derived: sum of 2 quarters · filed 2023-03-09
-$16.14M
derived: sum of 3 quarters · filed 2023-03-09
-$23.56M
10-K · filed 2023-03-09
2021-09-30-$4.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
-$10.26M
derived: sum of 2 quarters · filed 2022-11-10
-$17.69M
10-Q · filed 2022-11-10
-$23.33M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30-$5.42M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
-$12.84M
10-Q · filed 2022-08-11
-$18.48M
derived: sum of 3 quarters · filed 2022-08-11
-$23.33M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$7.42M
10-Q · filed 2022-05-12
-$13.06M
derived: sum of 2 quarters · filed 2022-05-12
-$17.91M
derived: sum of 3 quarters · filed 2022-05-12
-$22.15M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31-$5.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10
-$10.49M
derived: sum of 2 quarters · filed 2022-03-10
-$14.73M
derived: sum of 3 quarters · filed 2022-03-10
-$19.75M
10-K · filed 2022-03-10
2020-09-30-$4.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
-$9.09M
derived: sum of 2 quarters · filed 2021-11-10
-$14.11M
10-Q · filed 2021-11-10
-$19.64M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30-$4.24M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
-$9.27M
10-Q · filed 2021-08-12
-$14.79M
derived: sum of 3 quarters · filed 2021-08-12
-$22.23M
derived: sum of 4 quarters · filed 2021-08-12
2020-03-31-$5.03M
10-Q · filed 2021-05-13
-$10.55M
derived: sum of 2 quarters · filed 2021-05-13
-$17.99M
derived: sum of 3 quarters · filed 2021-05-13
-$27.66M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31-$5.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11
-$12.97M
derived: sum of 2 quarters · filed 2021-03-11
-$22.63M
derived: sum of 3 quarters · filed 2021-03-11
-$31.95M
10-K · filed 2021-03-11
2019-09-30-$7.44M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04
-$17.11M
derived: sum of 2 quarters · filed 2020-11-04
-$26.42M
10-Q · filed 2020-11-04
-$32.24M
derived: sum of 4 quarters · filed 2020-11-04
2019-06-30-$9.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
-$18.98M
10-Q · filed 2020-08-06
-$24.79M
derived: sum of 3 quarters · filed 2020-08-06
-$32.13M
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31-$9.31M
10-Q · filed 2020-05-07
-$15.13M
derived: sum of 2 quarters · filed 2020-05-07
-$22.46M
derived: sum of 3 quarters · filed 2020-05-07
-$29.86M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31-$5.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
-$13.14M
derived: sum of 2 quarters · filed 2020-03-12
-$20.54M
derived: sum of 3 quarters · filed 2020-03-12
-$30.88M
10-K · filed 2020-03-12
2018-09-30-$7.33M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
-$14.73M
derived: sum of 2 quarters · filed 2019-11-12
-$25.07M
10-Q · filed 2019-11-12
-$30.75M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30-$7.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
-$17.74M
10-Q · filed 2019-08-08
-$23.41M
derived: sum of 3 quarters · filed 2019-08-08
-$31.09M
derived: sum of 4 quarters · filed 2019-08-08
2018-03-31-$10.34M
10-Q · filed 2019-05-09
-$16.01M
derived: sum of 2 quarters · filed 2019-05-09
-$23.69M
derived: sum of 3 quarters · filed 2019-05-09
-$32.76M
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31-$5.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14
-$13.36M
derived: sum of 2 quarters · filed 2019-03-14
-$22.42M
derived: sum of 3 quarters · filed 2019-03-14
-$30.52M
10-K · filed 2019-03-14
2017-09-30-$7.68M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
-$16.74M
derived: sum of 2 quarters · filed 2018-11-08
-$24.84M
10-Q · filed 2018-11-08
-$33.69M
derived: sum of 4 quarters · filed 2018-11-08
2017-06-30-$9.06M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02
-$17.16M
10-Q · filed 2018-08-02
-$26.01M
derived: sum of 3 quarters · filed 2018-08-02
-$34.93M
derived: sum of 4 quarters · filed 2018-08-02
2017-03-31-$8.10M
10-Q · filed 2018-05-10
-$16.95M
derived: sum of 2 quarters · filed 2018-05-10
-$25.86M
derived: sum of 3 quarters · filed 2018-05-10
2016-12-31-$8.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15
-$17.77M
derived: sum of 2 quarters · filed 2018-03-15
-$42.33M
10-K · filed 2018-03-15
2016-09-30-$8.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
-$33.47M
10-Q · filed 2017-11-09
2016-06-30-$24.56M
10-Q · filed 2017-08-09
2015-12-31-$44.54M
10-K · filed 2018-03-15
2014-03-31-$10.36M
10-Q · filed 2014-05-12
-$18.98M
derived: sum of 2 quarters · filed 2014-05-12
-$25.40M
derived: sum of 3 quarters · filed 2014-05-12
-$32.84M
derived: sum of 4 quarters · filed 2014-05-12
2013-12-31-$8.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17
-$15.04M
derived: sum of 2 quarters · filed 2014-03-17
-$22.49M
derived: sum of 3 quarters · filed 2014-03-17
-$29.51M
10-K · filed 2014-03-17
2013-09-30-$6.42M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12
-$13.86M
derived: sum of 2 quarters · filed 2013-11-12
-$20.88M
10-Q · filed 2013-11-12
-$25.88M
derived: sum of 4 quarters · filed 2014-05-12
2013-06-30-$7.44M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09
-$14.47M
10-Q · filed 2013-08-09
-$19.46M
derived: sum of 3 quarters · filed 2014-05-12
-$24.47M
derived: sum of 4 quarters · filed 2014-05-12
2013-03-31-$7.02M
10-Q · filed 2014-05-12
-$12.02M
derived: sum of 2 quarters · filed 2014-05-12
-$17.03M
derived: sum of 3 quarters · filed 2014-05-12
-$20.98M
derived: sum of 4 quarters · filed 2014-05-12
2012-12-31-$5.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17
-$10.00M
derived: sum of 2 quarters · filed 2014-03-17
-$13.96M
derived: sum of 3 quarters · filed 2014-03-17
-$19.68M
10-K · filed 2014-03-17
2012-09-30-$5.01M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12
-$8.97M
derived: sum of 2 quarters · filed 2013-11-12
-$14.68M
10-Q · filed 2013-11-12
-$18.53M
derived: sum of 4 quarters · filed 2014-03-17
2012-06-30-$3.96M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09
-$9.67M
10-Q · filed 2013-08-09
-$13.52M
derived: sum of 3 quarters · filed 2014-03-17
-$17.12M
derived: sum of 4 quarters · filed 2014-03-17
2012-03-31-$5.72M
10-Q · filed 2013-05-10
-$9.56M
derived: sum of 2 quarters · filed 2014-03-17
-$13.16M
derived: sum of 3 quarters · filed 2014-03-17
-$15.95M
derived: sum of 4 quarters · filed 2014-03-17
2011-12-31-$3.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17
-$7.44M
derived: sum of 2 quarters · filed 2014-03-17
-$10.24M
derived: sum of 3 quarters · filed 2014-03-17
-$13.59M
10-K · filed 2014-03-17
2011-09-30-$3.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09
-$6.39M
derived: sum of 2 quarters · filed 2012-11-09
-$9.75M
10-Q · filed 2012-11-09
-$10.00M
10-Q · filed 2011-11-08
-$12.53M
derived: sum of 4 quarters · filed 2013-03-18
2011-06-30-$2.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
-$6.15M
10-Q · filed 2012-08-09
-$6.40M
10-Q · filed 2011-08-09
-$8.93M
derived: sum of 3 quarters · filed 2013-03-18
-$10.92M
derived: sum of 4 quarters · filed 2013-03-18
2011-03-31-$3.36M
10-Q · filed 2012-05-10
-$6.13M
derived: sum of 2 quarters · filed 2013-03-18
-$8.13M
derived: sum of 3 quarters · filed 2013-03-18
2010-12-31-$2.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18
-$4.77M
derived: sum of 2 quarters · filed 2013-03-18
-$7.73M
10-K · filed 2013-03-18
2010-09-30-$1.99M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08
-$4.96M
10-Q · filed 2011-11-08
2010-06-30-$2.96M
10-Q · filed 2011-08-09
2009-12-31-$4.26M
10-K · filed 2012-03-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
Alector, Inc. (ALEC)United States$0.213B-1.90
Invivyd, Inc. (IVVD)United States$0.270B-2.42
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51